Provided are an antiviral precursor drug nucleoside cyclophosphate compound based on liver specific delivery (LSD) technology and a use thereof, and in particular, provided are a compound of formula II and an isomer, pharmaceutically acceptable salt, hydrate, and solvate thereof, and the corresponding pharmaceutical composition. Also provided are the use of the compounds alone or in combination with other antiviral drugs in the treatment of hepatitis B virus (HBV), hepatitis D virus (HDV) and human immunodeficiency virus (HIV) and diseases caused by same.